New developments in the antiviral treatment of hepatitis C

Vox Sanguinis

Volumn 97, Issue 1, 2009, Pages 1-12

  De Bruijne, J ^a,b   Weegink, C J ^a   Jansen, P L M ^a   Reesink, H W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; ALBINTERFERON ALPHA2B; ANA 598; ANA 975; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; AVI 4065; BI 201335; BMS 790052; BOCEPREVIR; CASTANOSPERMINE 6 BUTYRATE; CHRONVAC C; CILUPREVIR; CPG 10101; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; GI 5005; GS9190; GSK 625433; HCV AB68; HEPATITIS C ANTIBODY; HEPATITIS C VACCINE; HEPTAZYME; IC 41; IDX 184; IMO 2125; ISATORIBINE; ISIS 14803; ITMN 191; LOCTERON; MIFEPRISTONE; MK 7009; NITAZOXANIDE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PF 00868554; PLACEBO; R 7128; RIBAVIRIN; RIBOZYME; TARIBAVIRIN; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; UNINDEXED DRUG; VCH 759;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTISENSE THERAPY; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BIOASSAY; CANCER RISK; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSGEUSIA; ERADICATION THERAPY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENE TARGETING; GENOTYPE; HEADACHE; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RASH; REVIEW; RIBOZYME THERAPY; RNA SEQUENCE; RNA TRANSLATION; TRANSLATION INITIATION; TRANSLATION REGULATION; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; VIRUS CULTURE; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSCRIPTION; VIRUS TRANSMISSION; WESTERN EUROPE;

ANIMALS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG EVALUATION, PRECLINICAL; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS;

EID: 67650489621     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2009.01187.x     Document Type: Review

References (52)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M : Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989 244 : 359 362 (Pubitemid 19117877)
2. Seeff LB : Natural history of chronic hepatitis C. Hepatology 2002 36 : S35 S46
3. Shepard CW, Finelli L, Alter MJ : Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005 5 : 558 567 (Pubitemid 41196755)
4. Lauer GM, Walker BD : Hepatitis C virus infection. N Engl J Med 2001 345 : 41 52 (Pubitemid 32634271)
5. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP : The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006 45 : 529 538 (Pubitemid 44307383)
6. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di BA, Peters M, Waggoner JG, Park Y, Jones EA : Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986 315 : 1575 1578 (Pubitemid 17055392)
7. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK : Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 : 1485 1492
8. Feld JJ, Hoofnagle JH : Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005 436 : 967 972 (Pubitemid 41191673)
9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK : Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965 (Pubitemid 32913521)
10. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J : Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982
11. Hadziyannis SJ, Sette H Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr., Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM : Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355
12. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M : Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 1999 77 : 801 807
13. Memon MI, Memon MA : Hepatitis C: an epidemiological review. J Viral Hepat 2002 9 : 84 100 (Pubitemid 36002471)
14. Prati D : Transmission of viral hepatitis by blood and blood derivatives: current risks, past heritage. Dig Liver Dis 2002 34 : 812 817 (Pubitemid 36097522)
15. Esteban JI, Sauleda S, Quer J : The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008 48 : 148 162 (Pubitemid 350191999)
16. Prati D : Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol 2006 45 : 607 616 (Pubitemid 44316867)
17. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin I, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A : Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005 42 : 962 973 (Pubitemid 41401136)
18. Wasley A, Alter MJ : Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000 20 : 1 16 (Pubitemid 30421405)
19. Lindenbach BD, Rice CM : Unravelling hepatitis C virus replication from genome to function. Nature 2005 436 : 933 938 (Pubitemid 41191668)
20. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM : Complete replication of hepatitis C virus in cell culture. Science 2005 309 : 623 626 (Pubitemid 41033648)
21. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R : Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999 285 : 110 113 (Pubitemid 29307577)
22. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD : Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007 132 : 1767 1777 (Pubitemid 46677938)
23. Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, Sapan CV, Riser LN, Li Y, Whitley RJ, Gnann JW Jr. : A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005 11 : 941 949 (Pubitemid 41122452)
24. Schiano TD, Charlton M, Younossi Z, Galun E, Pruett T, Tur-Kaspa R, Eren R, Dagan S, Graham N, Williams PV, Andrews J : Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 2006 12 : 1381 1389 (Pubitemid 44405128)
25. Soler M, McHutchison JG, Kwoh TJ, Dorr FA, Pawlotsky JM : Virological effects of ISIS 14 803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Antivir Ther 2004 9 : 953 968 (Pubitemid 40040269)
26. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagace L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St GR, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinas-Brunet M : An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003 426 : 186 189 (Pubitemid 37442587)
27. Lu L, Pilot-Matias TJ, Stewart KD, Randolph JT, Pithawalla R, He W, Huang PP, Klein LL, Mo H, Molla A : Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 2004 48 : 2260 2266 (Pubitemid 38691627)
28. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van VA, van de Wetering de Rooij McNair L, Purdy S, Kauffman R, Alam J, Jansen PL : Rapid decline of viral RNA in hepatitis C patients treated with VX-950:a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006 131 : 997 1002 (Pubitemid 44498690)
29. Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S : Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007 46 : 640 648 (Pubitemid 47436108)
30. Zeuzem S : Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients. J Hepatol 2008 49 : 157 159
31. McHutchison JG, Everson GT, Gordon SC, Jacobson I, Kauffman R, McNair L, Muir AJ, PROVE1: Results from a phase 2 study of telaprevir with Peginterferon alfa-2a and ribavirin in treatment-naïve subjects with hepatitis C. Presented at the 41st Annual Meeting of the European Association for the Study of the Liver April 23-27, 2008; Milan, Italy.
32. Zeuzem S, Hezode C, Ferenci P, Dusheiko GM, Alves K, Bengtsson L, Gharakhanian S, Kauffman R, Alam J, Pawlotsky JM : Telaprevir in combination with peginterferon-alfa-2a with or without ribavirin in the treatment of chronic hepatitis C: final results of the PROVE2 study. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases October 31-November 4, 2008; San Francisco, CA.
33. Mchutchison JG, Shiffman M, Terrault N, Manns MP, Di BA, Jacobson I, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink H, George S, Adda N, Muir AJ : A phase 2b study of telaprevir with peginterferon-alfa-2a and ribavirin in hepatitis C genotype 1 null and partial responders and relapsers following a prior course of peginterferon-alfa-2a/b and ribavirin therapy: PROVE3 interim results. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases October 31-November 4, 2008; San Francisco, CA.
34. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J, Zeuzem S : SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007 132 : 1270 1278
35. Kwo P, Lawitz E, McCone J, Schiff ER, Vierling JM, Pound D, Davis M, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson I, Rubin R, Koury K, Chaudhri EI, Albrecht JK : HCV SPRINT-1: boceprevir plus peginterferon-alfa-2b/ribavirin for treatment of genotype 1 chronic hepatitis C in previously untreated patients. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases October 31-November 4, 2008; San Francisco, CA.
36. Schiff ER, Poordad F, Jacobson I, Flamm S, Bacon B, Lawitz E, Gordon SC, Mchutchison JG, Ghalib R, Poynard T, Sulkowski M, Trepo C, Rizzetto M, Zeuzem S, Marcellin P, Mendez P, Brass C, Albrecht JK : Boceprevir (B) combination therapy in null responders (NR): Response dependent on interferon responsiveness. Presented at the 41st Annual Meeting of the European Association for the Study of the Liver April 23-27, 2008; Milan, Italy.
37. Reesink H, Verloes R, Abou Farha K, Van Vliet A, Weegink C, van't Klooster G, Aharchi F, Marien K, Van Remoortere P, de Kock H, Broeckaert F, Fanning G, Meyvisch P, Van Beirendonck E, Simmen K : Safety of the HCV protease inhibitor TMC435350 in healthy volunteers and safety and activity in chronic hepatitis C infected individuals: A phase 1 study. Presented at the 41st Annual Meeting of the European Association for the Study of the Liver April 23-27, 2008; Milan, Italy.
38. Roberts SK, Cooksley G, Dore GJ, Robson R, Shaw D, Berns H, Hill G, Klumpp K, Najera I, Washington C : Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008 48 : 398 406
39. Pockros PJ, Nelson D, Godofsky E, Rodriguez-Torres M, Everson GT, Fried MW, Ghalib R, Harrison S, Nyberg L, Shiffman ML, Najera I, Chan A, Hill G : R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008 48 : 385 397
40. Pockros P, Nelson D, Godofsky E, Rodriguez-Torres M, Everson GT, Fried MW, Ghalib R, Harrison S, Nyberg L, Shiffman ML, Chan A, Hill G : High relapse rate seen at week 72 for patients treated with R1626 combination therapy. Hepatology 2008 48 : 1349 1350
41. Reddy R, Rodriguez-Torres M, Gane E, Robson R, Lalezari J, Everson GT, DeJesus E, Mchutchison JG, Vargas HE, Beard A, Rodriguez CA, Hill G, Symonds W, Berrey M : Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases October 27-31, 2006, Boston, MA.
42. Gane E, Rodriguez-Torres M, Nelson D, Jacobson I, Mchutchison JG, Jeffers L, Beard A, Walker S, Shulman N, Symonds W, Albanis E, Berrey M : Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500 mg bid with peg-IFN and ribavirin for 28 days. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases October 31-November 4, 2008; San Francisco, CA.
43. Standring DN, Lanford R, Cretton-Scott E, Licklider L, Larsson M, Pierra C, Gosselin G, Perigaud C, Surleraux D, Mayes B, Moussa A, Selden J : Potent antiviral activity of second generation nucleoside inhibitors, IDX102 and IDX 184, in HCV-infected chimpanzees. Presented at the 41st Annual Meeting of the European Association for the Study of the Liver April 23-27, 2008; Milan, Italy.
44. Nicolas O, Boivin I, Bedard J : Genotypic analysis of HCV NS5B variants selected from patients treated with VCH-759. Presented at the 41st Annual Meeting of the European Association for the Study of the Liver April 23-27, 2008; Milan, Italy.
45. Nettles R, Chien C, Persson A, Min Gao Belema M, Meanwell NA, DeMicco M, Marbury TC, Goldwater R, Northup P, Coumbis J, Kraft WK, Charlton M, Lopez-Talavera JC, Grasela D : BMS-790052 is a first-in-class potent hepatitis C virus (HCV) NS5A inhibitor for patients with chronic HCV infection: Results from a proof-of-concept study. Presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases October 31-November 4, 2008, San Francisco, CA.
46. Flisiak R, Horban A, Gallay P, Bobardt M, Selvarajah S, Wiercinska-Drapalo A, Siwak E, Cielniak I, Higersberger J, Kierkus J, Aeschlimann C, Grosgurin P, Nicolas-Metral V, Dumont JM, Porchet H, Crabbe R, Scalfaro P : The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008 47 : 817 826
47. Flisiak R, Feinman SV, Jablowski M, Horban A, Kryczka W, Halota W, Heathcote JE, Mazzella G, Vandelli C, Liz JS, Crabbz R, Scalfaro P, Porchet H : Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon alpha-2a in treatment naïve chronic HCV patients. Presented at the 41st Annual Meeting of the European Association for the Study of the Liver April 23-27, 2008; Milan, Italy.
48. Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB : Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2008 April 23-27, 2008 28 : 574 580
49. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB : Randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4. Presented at the 41st Annual Meeting of the European Association for the Study of the Liver April 23-27, 2008; Milan, Italy.
50. McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, Jacobson IM, Muir A, Al-Adhami M, Morris ML, Lekstrom-Himes JA, Efler SM, Davis HL : Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007 46 : 1341 1349
51. Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, Steffy KR, Bauman LA, Kerr BM, Averett DR : Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005 42 : 724 731 (Pubitemid 41233667)
52. Gish RG, Arora S, Rajender RK, Nelson DR, O'Brien C, Xu Y, Murphy B : Virological response and safety outcomes in therapy- naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol 2007 47 : 51 59 (Pubitemid 46817694)